Cowen Starts AMAG Pharmaceuticals (AMAG) at Outperform

Cowen initiates coverage on AMAG Pharmaceuticals (NASDAQ: AMAG) with a Outperform rating and a price target of $65.00.

Analyst Ken Cacciatore commented, "The acquisition of the Lumara assets has created a strongly cash generative platform in which management should be able to leverage and create additional value. Upside from further market penetration of Makena – and likely extension of its duration longer than currently assumed – should provide a nice runway for the accumulation of other complementary, accretive, and NPV positive assets. Buy here."

For an analyst ratings summary and ratings history on AMAG Pharmaceuticals click here. For more ratings news on AMAG Pharmaceuticals click here.

Shares of AMAG Pharmaceuticals closed at $51.58 yesterday.

You May Also Be Interested In

• Marvell (MRVL) PT Raised to $225 at TD Cowen
• Stifel Downgrades Weave Communications Inc (WEAV) to Hold
• Outlook Therapeutics Inc. (OTLK) PT Lowered to $4 at Brookline Capital Markets